{"id":703609,"date":"2024-06-21T16:24:01","date_gmt":"2024-06-21T16:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=703609"},"modified":"2024-06-21T16:24:01","modified_gmt":"2024-06-21T16:24:01","slug":"advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_703609.html","title":{"rendered":"Advanced Non-Squamous &#038; Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1718953171.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Advanced Non-Squamous &amp; Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1718953171.jpeg\" alt=\"Advanced Non-Squamous &amp; Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Insight, 2024,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about&nbsp;<strong>9+ companies and 11+ pipeline drugs<\/strong>&nbsp;in Advanced Non-Squamous &amp; Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous &amp; Squamous NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Non-Squamous &amp; Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in Advanced Non-Squamous &amp; Squamous NSCLC Research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><em><strong>June 2024:- Summit Therapeutics<\/strong><\/em>&#8211; A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi).<\/li>\n<li><em><strong>June 2024:- AstraZeneca<\/strong><\/em>&#8211; The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC &ge; 50%) and without actionable genomic alterations.<\/li>\n<li><em><strong>June 2024:- AbbVie<\/strong><\/em>&#8211; A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced\/Metastatic Non-Squamous Non-Small Cell Lung Cancer.<\/li>\n<li><em><strong>June 2024:- Arcus Biosciences Inc.<\/strong><\/em>&#8211; A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.<\/li>\n<li><em><strong>June 2024:- Genelux Corporation<\/strong><\/em>&#8211; A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician&#8217;s Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance.<\/li>\n<li><em><strong>June 2024:- Boehringer Ingelheim-<\/strong><\/em> Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations.<\/li>\n<li><em><strong>June 2024:- Mabscale LLC<\/strong><\/em>-BEV-III\/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin&reg; and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin&reg;.<\/li>\n<li>DelveInsight&rsquo;s Advanced Non-Squamous &amp; Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 11+ pipeline therapies for Advanced Non-Squamous &amp; Squamous NSCLC treatment.<\/li>\n<li>The leading Advanced Non-Squamous &amp; Squamous NSCLC Companies such as <em><strong>Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech,<\/strong><\/em> and others.<\/li>\n<li>Promising Advanced Non-Squamous &amp; Squamous NSCLC Therapies such as <em><strong>Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine)<\/strong><\/em>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in Advanced Non-Squamous &amp; Squamous NSCLC Treatments. Download for updates and be a part of the revolution in cancer care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Erfonrilimab: Jiangsu Alphamab Biopharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">KN-046 (Erfonrilimab) is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being evaluated under the Phase III clinical trial for the treatment of Advanced Squamous Non-small Cell Lung Cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Pyrotinib: Jiangsu HengRui Medicine<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from advanced non-squamous NSCLC.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about Advanced Non-Squamous &amp; Squamous NSCLC Drugs opportunities in our groundbreaking Advanced Non-Squamous &amp; Squamous NSCLC Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Subcutaneous<\/li>\n<li>Intravitreal<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibody<\/li>\n<li>Small molecule<\/li>\n<li>Peptide<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in Advanced Non-Squamous &amp; Squamous NSCLC Treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of oncology @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC<\/strong> <strong>Companies and Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ribon Therapeutics Inc.: RBN-2397<\/li>\n<li>Summit Therapeutics:- AK112 Injection<\/li>\n<li>Jiangsu HengRui Medicine Co., Ltd.:- Pyrotinib\/Docetaxel<\/li>\n<li>Sanofi:- SAR408701 (Tusamitamab ravtansine)<\/li>\n<li>Shanghai Shengdi Pharmaceutical Co., Ltd:- Adebrelimab+SHR-8068+Pemetrexed+Carboplatin<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Therapies- Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine), and others.<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of Advanced Non-Squamous &amp; Squamous NSCLC Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Pyrotinib: Jiangsu HengRui Medicine<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Key Companies<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Key Products<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Unmet Needs<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Market Drivers and Barriers<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Future Perspectives and Conclusion<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Analyst Views<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Insight, 2024,&rdquo;&nbsp;report provides comprehensive insights about&nbsp;9+ companies and 11+ pipeline drugs&nbsp;in Advanced Non-Squamous &amp; Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous &amp; Squamous NSCLC pipeline drug profiles, including clinical and nonclinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/advanced-nonsquamous-squamous-nsclc-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_703609.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-703609","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=703609"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703609\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=703609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=703609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=703609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}